New drug combo aims to revive immune response in lung cancer
Disease control
Recruiting now
This phase 3 trial tests whether a new drug called THIO, given before the immunotherapy cemiplimab, can help people with advanced non-small cell lung cancer who have already tried two prior treatments. About 300 participants will be randomly assigned to receive either the THIO-ce…
Phase: PHASE3 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC